Eli Lilly’s October 2024 non-exclusive research agreement with Peptron granted only evaluation rights to SmartDepot, its ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release, without commercial manufacturing or licensing terms. Nearly two years later, no technology-transfer or binding commercial deal has been announced. Trader sentiment has been shaped by Lilly’s June 2026 partnership with Camurus for the competing FluidCrystal long-acting platform targeting incretins, which raised doubts about SmartDepot’s priority. With roughly two months remaining until the October 7 resolution date and limited recent public progress signals, the market-implied 87.5% probability on “No” reflects the absence of concrete catalysts capable of shifting the timeline.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日13% 確率
$11,264 Vol.
$11,264 Vol.
2026/10/07
13% 確率
$11,264 Vol.
$11,264 Vol.
2026/10/07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 non-exclusive research agreement with Peptron granted only evaluation rights to SmartDepot, its ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release, without commercial manufacturing or licensing terms. Nearly two years later, no technology-transfer or binding commercial deal has been announced. Trader sentiment has been shaped by Lilly’s June 2026 partnership with Camurus for the competing FluidCrystal long-acting platform targeting incretins, which raised doubts about SmartDepot’s priority. With roughly two months remaining until the October 7 resolution date and limited recent public progress signals, the market-implied 87.5% probability on “No” reflects the absence of concrete catalysts capable of shifting the timeline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
マーケット開始日： May 5, 2026, 8:02 PM ET
音量
$11,264終了日
2026/10/07マーケット開始日
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 non-exclusive research agreement with Peptron granted only evaluation rights to SmartDepot, its ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release, without commercial manufacturing or licensing terms. Nearly two years later, no technology-transfer or binding commercial deal has been announced. Trader sentiment has been shaped by Lilly’s June 2026 partnership with Camurus for the competing FluidCrystal long-acting platform targeting incretins, which raised doubts about SmartDepot’s priority. With roughly two months remaining until the October 7 resolution date and limited recent public progress signals, the market-implied 87.5% probability on “No” reflects the absence of concrete catalysts capable of shifting the timeline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
音量
$11,264終了日
2026/10/07マーケット開始日
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 non-exclusive research agreement with Peptron granted only evaluation rights to SmartDepot, its ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release, without commercial manufacturing or licensing terms. Nearly two years later, no technology-transfer or binding commercial deal has been announced. Trader sentiment has been shaped by Lilly’s June 2026 partnership with Camurus for the competing FluidCrystal long-acting platform targeting incretins, which raised doubts about SmartDepot’s priority. With roughly two months remaining until the October 7 resolution date and limited recent public progress signals, the market-implied 87.5% probability on “No” reflects the absence of concrete catalysts capable of shifting the timeline.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問